Portland, Oregon 97239


This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks.

Study summary:

This study will use a two-part, multicenter, dose-titration study in pediatric patients with a detrusor overactivity associated with a neurological condition


Inclusion Criteria: - 3 years to < 17 years - Neurogenic bladder - Neurological condition - CIC Exclusion Criteria: - Have anatomical bladder abnormalities - Sensitivity to anticholinergics - Bladder augmentation



Primary Contact:

Study Director
Anna Chan
Allergan Sales, LLC

Clinical Trials Registry Team
Phone: 1-877-277-8566
Email: IR-CTRegistration@allergan.com

Backup Contact:


Location Contact:

Portland, Oregon 97239
United States

Site Coordinator
Phone: 503-494-8216

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.